title: Near-infrared light triggers release of Paclitaxel from biodegradable microspheres: photothermal effect and enhanced antitumor activity.
abstract: Despite advances in controlled drug delivery, reliable methods for activatable, high-resolution control of drug release are needed. The hypothesis that the photothermal effect mediated by a near-infrared (NIR) laser and hollow gold nanospheres (HAuNSs) could modulate the release of anticancer agents is tested with biodegradable and biocompatible microspheres (1-15 microm) containing the antitumor drug paclitaxel (PTX) and HAuNSs (approximately 35 nm in diameter), which display surface plasmon absorbance in the NIR region. HAuNS-containing microspheres exhibit a NIR-induced thermal effect similar to that of plain HAuNSs. Rapid, repetitive PTX release from the PTX/HAuNS-containing microspheres is observed upon irradiation with NIR light (808 nm), whereas PTX release is insignificant when the NIR light is switched off. The release of PTX from the microspheres is readily controlled by the output power of the NIR laser, duration of irradiation, treatment frequency, and concentration of HAuNSs embedded inside the microspheres. In vitro, cancer cells incubated with PTX/HAuNS-loaded microspheres and irradiated with NIR light display significantly greater cytotoxic effects than cells incubated with the microspheres alone or cells irradiated with NIR light alone, owing to NIR-light-triggered drug release. Treatment of human U87 gliomas and MDA-MB-231 mammary tumor xenografts in nude mice with intratumoral injections of PTX/HAuNS-loaded microspheres followed by NIR irradiation results in significant tumor-growth delay compared to tumors treated with HAuNS-loaded microspheres (no PTX) and NIR irradiation or with PTX/HAuNS-loaded microspheres alone. The data support the feasibility of a therapeutic approach in which NIR light is used for simultaneous modulation of drug release and induction of photothermal cell killing.
authors.affiliation: Department of Experimental Diagnostic Imaging, Unit 59, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
authors.forename: Jian
authors.initials: J
authors.lastname: You
authors.forename: Ruping
authors.initials: R
authors.lastname: Shao
authors.forename: Xin
authors.initials: X
authors.lastname: Wei
authors.forename: Sanjay
authors.initials: S
authors.lastname: Gupta
authors.forename: Chun
authors.initials: C
authors.lastname: Li
mesh_terms: D020341:Absorbable Implants; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry; D045744:Cell Line, Tumor; D003692:Delayed-Action Preparations / Q000008:administration & dosage* / Q000737:chemistry* / Q000528:radiation effects*; D004058:Diffusion; D005910:Glioma / Q000188:drug therapy* / Q000473:pathology; D006046:Gold / Q000737:chemistry; D006358:Hot Temperature; D006801:Humans; D007259:Infrared Rays; D046911:Macromolecular Substances / Q000737:chemistry; D008422:Materials Testing; D008863:Microspheres; D008968:Molecular Conformation; D049329:Nanostructures / Q000008:administration & dosage / Q000737:chemistry* / Q000648:ultrastructure; D017239:Paclitaxel / Q000008:administration & dosage / Q000737:chemistry*; D013499:Surface Properties
chemical_list: D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D046911:Macromolecular Substances; D006046:Gold; D017239:Paclitaxel
references.citation: Nanomedicine (Lond). 2008 Feb;3(1):31-43
references.pmid: 18393665
references.citation: Photochem Photobiol. 2009 Jul-Aug;85(4):848-60
references.pmid: 19222790
references.citation: Biomacromolecules. 2007 Aug;8(8):2450-6
references.pmid: 17661518
references.citation: Expert Opin Pharmacother. 2008 Oct;9(15):2603-16
references.pmid: 18803448
references.citation: Technol Cancer Res Treat. 2004 Feb;3(1):33-40
references.pmid: 14750891
references.citation: Int J Pharm. 2005 Jan 20;288(2):315-23
references.pmid: 15620872
references.citation: Adv Drug Deliv Rev. 2001 Dec 31;53(3):285-305
references.pmid: 11744173
references.citation: ACS Nano. 2009 Oct 27;3(10):3184-90
references.pmid: 19769339
references.citation: J Pharm Sci. 1997 Dec;86(12):1458-63
references.pmid: 9423162
references.citation: Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13549-54
references.pmid: 14597719
references.citation: Lung Cancer. 2005 Dec;50(3):355-74
references.pmid: 16139391
references.citation: Adv Drug Deliv Rev. 2001 Dec 31;53(3):265-72
references.pmid: 11744171
references.citation: ACS Nano. 2008 Sep 23;2(9):1807-16
references.pmid: 19206419
references.citation: Nat Biotechnol. 2001 Apr;19(4):316-7
references.pmid: 11283581
references.citation: Clin Cancer Res. 2009 Feb 1;15(3):876-86
references.pmid: 19188158
references.citation: J Am Chem Soc. 2006 Feb 15;128(6):2115-20
references.pmid: 16464114
references.citation: J Control Release. 2007 Nov 20;123(3):219-27
references.pmid: 17920154
references.citation: Curr Opin Oncol. 2005 May;17(3):218-24
references.pmid: 15818164
references.citation: J Control Release. 2007 Oct 18;123(1):19-26
references.pmid: 17826863
references.citation: Small. 2007 May;3(5):804-8
references.pmid: 17385759
references.citation: J Natl Cancer Inst. 1990 Aug 1;82(15):1247-59
references.pmid: 1973737
references.citation: J Magn Reson Imaging. 2008 Feb;27(2):400-9
references.pmid: 18219675
references.citation: Mol Cancer Ther. 2008 Jun;7(6):1730-9
references.pmid: 18566244
references.citation: Adv Drug Deliv Rev. 2008 Jun 30;60(10):1153-66
references.pmid: 18486268
references.citation: J Am Chem Soc. 2003 Apr 16;125(15):4451-9
references.pmid: 12683815
references.citation: J Am Chem Soc. 2008 Jul 2;130(26):8175-7
references.pmid: 18543914
references.citation: Bioconjug Chem. 1999 Nov-Dec;10(6):1150-2
references.pmid: 10563787
references.citation: J Am Chem Soc. 2006 Sep 6;128(35):11720-6
references.pmid: 16939297
references.citation: Int J Pharm. 2007 Sep 5;342(1-2):6-17
references.pmid: 17555895